Cancer and Metastasis Reviews

Papers
(The TQCC of Cancer and Metastasis Reviews is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer172
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities166
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression134
The functions and modifications of tRNA-derived small RNAs in cancer biology96
Clonal tracking in cancer and metastasis88
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective73
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions69
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms67
The role of microbiome in pancreatic cancer62
Obesity and cancer57
Regulation of dormancy during tumor dissemination: the role of the ECM47
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?47
Targeting lipid metabolism in cancer: neuroblastoma46
The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor46
Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations46
CAR T-cell therapy to treat multiple myeloma: current state and future directions46
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer44
Cell-cell interactions mediating primary and metastatic breast cancer dormancy43
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond41
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review40
Correction to: Cutting the edge between cancerogenesis and organogenesis of the pancreatic endocrine lineage allocation—comprehensive review of the genes Synaptotagmin 13 and 533041C22 Rik in epitheli39
p73 isoforms meet evolution of metastasis36
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?36
Preface35
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives35
Biography—Mathieu Boissan, Pharm.D., Ph.D35
A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients35
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer34
Neuropeptide Y in cancer—biological functions and potential clinical implications33
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance33
Biographies31
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications31
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy30
Biographies30
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance29
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis27
Targeting DNA damage repair pathways in pancreas cancer27
Short-chain fatty acids in cancer pathogenesis26
The role of cancer cell bioenergetics in dormancy and drug resistance26
Clusterin: a marker and mediator of chemoresistance in colorectal cancer26
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development25
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy25
Tumor necrosis factor superfamily signaling: life and death in cancer24
Clinical interventions to break the obesity and cancer link: a narrative review23
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions23
Vaping and tumor metastasis: current insights and progress23
Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology23
Functional and clinical roles of stromal PDGF receptors in tumor biology22
The emerging roles of histone demethylases in cancers22
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy22
Impact of posttranslational modifications in pancreatic carcinogenesis and treatments21
Carcinoma of unknown primary (CUP): an update for histopathologists21
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions21
Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review20
Debris-stimulated tumor growth: a Pandora’s box?20
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution20
OX40/OX40 ligand and its role in precision immune oncology20
Kenneth V. Honn, Ph.D. (1946–2023)20
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape20
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy19
HOXA9 transcription factor is a double-edged sword: from development to cancer progression19
Inflammatory bowel disease and carcinogenesis19
New progress of tuberculosis scar carcinoma19
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting19
Ferroptosis: iron release mechanisms in the bioenergetic process18
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies18
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect18
The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance18
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective17
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases16
Biographies16
Metastasis suppressor genes in clinical practice: are they druggable?16
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs16
Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment16
Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX16
The role of circular RNA during the urological cancer metastasis: exploring regulatory mechanisms and potential therapeutic targets16
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases16
Is cancer an intelligent species?16
Metastasis suppressor genes and their role in the tumor microenvironment16
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics16
0.16576313972473